<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Exp Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Exp Immunol</journal-id><journal-id journal-id-type="publisher-id">cei</journal-id><journal-title-group><journal-title>Clinical and Experimental Immunology</journal-title></journal-title-group><issn pub-type="ppub">0009-9104</issn><issn pub-type="epub">1365-2249</issn><publisher><publisher-name>Blackwell Science Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17302892</article-id><article-id pub-id-type="pmc">PMC1810488</article-id><article-id pub-id-type="doi">10.1111/j.1365-2249.2006.03294.x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>Effect and mechanism of lipopolysaccharide on allergen-induced
interleukin-5 and eotaxins production by whole blood cultures of atopic
asthmatics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Min</surname><given-names>J-W</given-names></name><xref rid="au1" ref-type="aff">*</xref><xref rid="fn1" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>S-M</given-names></name><xref rid="au1" ref-type="aff">*</xref><xref rid="fn1" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Rhim</surname><given-names>T Y</given-names></name><xref rid="au1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>S-W</given-names></name><xref rid="au1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>Jang</surname><given-names>A-S</given-names></name><xref rid="au1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>Uh</surname><given-names>S-T</given-names></name><xref rid="au1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>C-S</given-names></name><xref rid="au1" ref-type="aff">*</xref><xref rid="fn1" ref-type="author-notes">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>I Y</given-names></name><xref rid="au2" ref-type="aff">&#x02020;</xref></contrib><aff id="au1"><label>*</label><institution>Genome Research Center for Allergy
and Respiratory Diseases, Division of Allergy and Respiratory Medicine,
Soonchunhyang University Bucheon Hospital</institution>
<addr-line>Korea</addr-line></aff><aff id="au2"><label>&#x02020;</label><institution>Division of Molecular and Life
Science, Hanyang University</institution>
<addr-line>Korea</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Correspondence: Dr Choon-Sik Park, Division of Allergy and
Respiratory Medicine, Soonchunhyang University Bucheon Hospital, 1174, Jung
Dong, Wonmi Ku, Bucheon, Gyeonggi Do, 420&#x02013;021, Republic of Korea. E-mail:
<email>mdcspark@unitel.co.kr</email></corresp><fn id="fn1"><label>&#x02021;</label><p>Ji-Won Min and Se-Min Park equally contributed to this work.</p><p>Re-use of this article is permitted in accordance with the Creative Commons
Deed, Attribution 2.5, which does not permit commercial exploitation.</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2007</year></pub-date><pub-date pub-type="pmc-release"><month>3</month><year>2007</year></pub-date><volume>147</volume><issue>3</issue><fpage>440</fpage><lpage>448</lpage><history><date date-type="accepted"><day>21</day><month>11</month><year>2006</year></date></history><permissions><copyright-statement>&#x000a9; 2007 The Author(s); Journal compilation &#x000a9; 2007
British Society for Immunology</copyright-statement><copyright-year>2007</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/2.5/</ali:license_ref><license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution
2.5, which does not permit commercial exploitation.</license-p></license></permissions><abstract><p>Interleukin (IL)-5 and eotaxin families regulate the development of eosinophilic
inflammation of asthma in a co-operative manner. The exposure to airborne
lipopolysaccharide (LPS) induces varying degrees of airflow obstruction and
neutrophilic airway inflammation. Production of IL-5 and eotaxin subfamily
chemokines was analysed in response to <italic>Dermatophagoides
pteronyssinus</italic> allergen (D.p.) according to the presence of specific
IgE to D.p., and investigated the mechanism underlying their LPS-mediated
regulation of these cytokines in response to the specific allergen. Peripheral
blood cells (PBCs) from asthmatics with (group 1) or without (group 2) specific
IgE to D.p. and from non-asthmatics with (group 3) or without (group 4) were
stimulated with D.p. or LPS. For LPS-mediated inhibition of IL-5 and eotaxin-2
production, LPS-induced cytokines were added to the D.p.-stimulated PBCs. IL-5
and eotaxin-2, but not eotaxin-1 and 3, were significantly increased by
D.p.-stimulated-PBCs from group 1, while only eotaxin-2 was elevated in group 3.
Eotaxin-2 production was found in monocytes and correlated with the level of
specific IgE to D.p. LPS treatment resulted in the decrease in eotaxin-2 and
IL-5 production by the D.p.-stimulated PBCs. LPS-induced IL-10 completely
inhibited D.p.-stimulated production of eotaxin-2 and IL-5. The differential
responses of the eotaxin family to specific antigens suggest that the
predominant role of eotaxin-2 and LPS may attenuate eosinophilic inflammation by
inhibiting IL-5 and eotaxin-2 synthesis through IL-10 production.</p></abstract><kwd-group><kwd>asthma</kwd><kwd>D.p. antigen</kwd><kwd>eotaxin-2</kwd><kwd>interleukin-10</kwd><kwd>interleukin-5</kwd><kwd>LPS</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Allergic asthma has been regarded as an atopic disease involving allergen exposure,
allergic (IgE-mediated) sensitization with a Th2 CD4<sup>+</sup> lymphocyte
response and subsequent interleukin (IL)-5-mediated eosinophilic airways
inflammation, resulting in enhanced bronchial reactivity and reversible airflow
obstruction [<xref rid="b1" ref-type="bibr">1</xref>]. In this
process, antigen-sensitized T helper 2 (Th2) cells play a key role in development of
the manifestations through their production and release of specific cytokines, such
as IL-4, IL-5 and IL-13 [<xref rid="b2" ref-type="bibr">2</xref>]. The
eotaxin subfamily, a member of CC chemokines, also participates in the development
of asthma and other allergic disorders through the mobilization of inflammatory
cells bearing CCR3, especially eosinophils. The potent effects of eotaxins on
eosinophils in concert with IL-5 are explained largely by their ability to signal
through the CCR3 [<xref rid="b3" ref-type="bibr">3</xref>]. Three
members of this family have been identified: eotaxin-1 [<xref rid="b4" ref-type="bibr">4</xref>], eotaxin-2 [<xref rid="b5" ref-type="bibr">5</xref>] and eotaxin-3 [<xref rid="b6" ref-type="bibr">6</xref>], and the three eotaxins share the same CCR3 [<xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b8" ref-type="bibr">8</xref>]. While limited studies have demonstrated their differential
expression and their roles in regulating the kinetics of eosinophil recruitment
during allergic inflammation [<xref rid="b9" ref-type="bibr">9</xref>&#x02013;<xref rid="b12" ref-type="bibr">12</xref>], the
eotaxins/CCR3 pathway evidently plays a fundamental role in eosinophil
recruitment in experimental allergic asthma [<xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b13" ref-type="bibr">13</xref>]. In
allergen-sensitized atopic asthmatic subjects, <italic>in vitro</italic> allergen
stimulation induces IL-5 production by peripheral blood mononuclear cells (PBMC)
[<xref rid="b14" ref-type="bibr">14</xref>]; however, it has not
been evaluated whether the synthesis of eotaxins depends on antigen
sensitization.</p><p>The exposure to airborne lipopolysaccharide (LPS) induces varying degrees of airflow
obstruction and neutrophil inflammation and is often associated with an exacerbation
of established asthma in children and adults [<xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b16" ref-type="bibr">16</xref>]. However, emerging
evidence suggests that exposure to endotoxin in early life prevents the development
of atopy and, potentially, allergic asthma [<xref rid="b17" ref-type="bibr">17</xref>&#x02013;<xref rid="b19" ref-type="bibr">19</xref>]. The
inhibitory effect of LPS is mediated presumably by the induction of Th1 cytokines
such as interferon (IFN)-&#x000e3; and IL-12 secretion [<xref rid="b18" ref-type="bibr">18</xref>,<xref rid="b20" ref-type="bibr">20</xref>,<xref rid="b21" ref-type="bibr">21</xref>] or regulatory cytokines such as
IL-10 [<xref rid="b22" ref-type="bibr">22</xref>]. However, the effect
and mechanisms of LPS on antigen-sensitized IL-5 and eotaxins production has not yet
been evaluated. In this study, we employed an <italic>ex vivo</italic> stimulation
of peripheral whole blood cells (PBCs) that were obtained from four groups of
asthmatics and non-asthmatics with or without specific IgE to mite
<italic>Dermatophagoides pteronyssinus</italic> (D.p.). The production of
cytokines and eotaxin subfamily chemokines in response to the mite antigen and the
mechanism(s) underlying their LPS-mediated regulation were analysed.</p></sec><sec><title>Methods</title><sec><title>Subjects</title><p>The study subjects comprised four groups: asthmatics with (group 1) or without
(group 2) D.p.-specific IgE, normal controls with (group 3) or without (group
4). The asthmatics had clinical symptoms and physical characteristics compatible
with the Global Initiative for Asthma (GINA) guidelines [<xref rid="b23" ref-type="bibr">23</xref>]. Asthmatics showed airway
reversibility, as documented by an inhalant bronchodilator-induced improvement
of more than 15% of forced expiratory volume in 1 second
(FEV<sub>1</sub>) and/or an airway hyper-responsiveness (AHR) to &#x0003c;
10 mg methacholine/ml [<xref rid="b24" ref-type="bibr">24</xref>]. Allergy skin prick tests were performed using 24 commercial
inhalant allergens, which included dust mites (<italic>Dermatophagoides
farinae</italic> and <italic>D. pteronyssinus</italic>, Bencard, West
Sussex, UK) and histamine (1 mg/ml). IgE specific to D.p. was measured
using the CAP system (Pharmacia Diagnostics, Uppsala, Sweden) and was presented
as specific IgE class (1&#x02013;6) according to UniCap-specific IgE Unites
(kU<sub>A</sub>/l). All subjects gave informed consent to participate
in the study, and the protocols were approved by the local ethics committee of
Soonchunhyang University Hospital.</p></sec><sec><title>Cell culture and cytokine/chemokine production</title><p>Peripheral blood was diluted at a 1 : 1 ratio with tissue culture medium
containing RPMI-1640, 2 m<sc>m l</sc>-glutamine, 25 mM HEPES, 100 U
penicillin/ml and 100 &#x000b5;g streptomycin/ml (JBI, Daegu,
Korea). PBCs were stimulated with various concentrations of D.p., which was
generously gifted by Professor Hong [<xref rid="b25" ref-type="bibr">25</xref>], and LPS (<italic>Escherichia coli</italic> 0111:B4,
L-2630) (Sigma, St. Louis, MO, USA) for different lengths of time. The culture
supernatants were harvested by centrifugation and were stored at
&#x02212;20&#x000b0;C until assayed. The potency of the D.p. was measured by
specific IgE inhibition test with the pooled sera of 10 asthmatics having
specific IgE (score &#x0003e; 4), as described previously [<xref rid="b26" ref-type="bibr">26</xref>]. Fifty per cent inhibition was
obtained by preincubation of the pooled serum with 10 &#x000b5;g D.p.
extract/ml. The endotoxin concentration of the mixture containing 10
&#x000b5;g D.p./ml was &#x0003c; 0&#x000b7;283 EU/ml (equivalent to
28&#x000b7;3 pg/ml), as determined by a limulus amoebocyte lysate kit
(Bio-Whittaker, Walkersville, MD, USA).</p></sec><sec><title>Measurement of cytokine and chemokine concentrations</title><p>Cytokine and eotaxin concentrations were determined by enzyme-linked
immunosorbent assay (ELISA), using kits from R&#x00026;D Systems (Minneapolis,
MN, USA) for eotaxin-2, and eotaxin-3 and kits from BD Biosciences (San Diego,
CA, USA) for eotaxin-1, IL-5, IFN-&#x003b3;, IL-12 and IL-10. The detection
limits for eotaxin-1, eotaxin-2, eotaxin-3, IL-5, IFN-&#x003b3;, IL-12 and IL-10
were 6&#x000b7;3, 15&#x000b7;6, 62&#x000b7;5, 3&#x000b7;9, 18&#x000b7;7, 31&#x000b7;3
and 15&#x000b7;6 pg/ml, respectively. All concentrations below these
limits were considered as the detection limit values above for the statistical
analysis. The inter- and intra-assay coefficients of variance were below
10%.</p></sec><sec><title>Immunocytochemical detection of intracellular eotaxin-2</title><p>Peripheral blood leucocytes were isolated from the venous blood of D.p.-specific
IgE-positive asthmatics using a Percoll gradient solution. A total of 1 &#x000d7;
10<sup>7</sup> cells were cultured for 72 h in the presence of autologous
serum (10% v/v) and 10 &#x000b5;g D.p./ml, with 3 &#x000b5;M
monensin (Sigma, M5273) added 6 h before the termination of culture. The
cultured cells were cytocentrifuged and fixed with 1% paraformaldehyde
and 0&#x000b7;1% saponin. Eotaxin-2-positive cells were identified by
immunostaining with anti-human eotaxin-2 (R&#x00026;D Systems) and biotinylated
goat-anti-mouse IgG (Vector Laboratories, Burlingame, CA, USA). The negative
control was incubated with isotype-matched antibody. The cells were then
counterstained with Wright&#x02013;Giemsa.</p></sec><sec><title>Inhibition and blocking of cytokine production in PBCs stimulated with
D.p.</title><p>For inhibition studies, various concentrations of IL-10, IL-12 (R&#x00026;D
Systems) and IFN-&#x003b3; (BD Bioscience) were added to PBCs in the presence of
D.p. (10 &#x000b5;g/ml). For blocking, PBCs were pretreated for 30 min
with various concentrations of mouse anti-human IL-10R&#x003b1; antibody
(R&#x00026;D Systems) or mouse anti-human TLR4 antibody (BD Bioscience) and then
for 72 h with D.p. (10 &#x000b5;g/ml) or LPS (10 ng/ml).</p></sec><sec><title>Reverse transcriptase&#x02013;polymerase chain reaction
(RT&#x02013;PCR)</title><p>PBCs from group 1 were stimulated for 72 h with D.p. in the presence or absence
of LPS and/or various concentrations of anti-IL-10R&#x003b1;. PBMCs were
then isolated from the cultured PBCs. Total RNA was extracted and
reverse-transcribed by incubation with 200 U SuperScript RT (Invitrogen Life
Technologies, Grand Island, NY, USA) at 42&#x000b0;C for 50 min. The resulting
cDNA were placed into tubes containing specific primer pairs for human
eotaxin-2, IL-5 or glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) gene, and
were amplified for 30 cycles (one cycle: 1 min at 95&#x000b0;C, 1 min at
55&#x000b0;C and 1 min at 72&#x000b0;C). The PCR products were resolved by agarose
(1%) gel electrophoresis. The primers used were follows; eotaxin-2
forward primer 5&#x02032;-GCTCTGTGGTCATCCCCTCTCCCTG-3&#x02032;, reverse primer
5&#x02032;-GCAGGTGGTTT GGTTCCAGGATAT-3&#x02032;; IL-5 forward primer 5&#x02032;-GAG
GATGCTTCTGCATTTGAGTTTG-3&#x02032;, reverse primer
5&#x02032;-GTCAATGTATTTCTTTATTAAGGACAAG-3&#x02032;; GAPDH forward primer
5&#x02032;-GGCATTGCTCTC AATGACAA-3&#x02032;, reverse primer 5&#x02032;-AGGGCCTC TCT
CTTGCTCTC-3&#x02032;.</p></sec><sec><title>Statistical analysis</title><p>Data were expressed as mean &#x000b1; s.e.m. Statistical analysis was carried out
using the <sc>spss</sc> program (version 11&#x000b7;0; SPSS Inc., Chicago, IL,
USA). Differences between independent groups or samples were compared using the
non-parametric Kruskal&#x02013;Wallis <italic>H</italic>-test for continuous
data. If differences were found to be significant, the Mann&#x02013;Whitney
<italic>U</italic>-test was applied to compare differences between two
samples. The Wilcoxon signed rank test was applied for time-dependent changes in
the parameters. Spearman's rank correlation was calculated to assess
correlations between data.</p></sec></sec><sec><title>Results</title><sec><title>Subject details</title><p>Asthmatics (groups 1 and 2) had significantly lower FEV<sub>1</sub> and
methacholine PC<sub>20</sub> values than did non-asthmatics (groups 3 and 4),
while the former exhibited higher blood eosinophil levels than the latter.
Specific and total IgE were significantly higher in the subjects allergic to
D.p. (groups 1 and 3) than in the non-allergic groups (groups 2 and 4) (<xref rid="tbl1" ref-type="table">Table 1</xref>). These findings are consistent
with previously described criteria [<xref rid="b27" ref-type="bibr">27</xref>].</p><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Clinical profiles of the study subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Asthma</th><th align="center" colspan="2" rowspan="1">Normal control</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1">
<hr/>
</th><th align="left" colspan="2" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1">Group 3</th><th align="center" rowspan="1" colspan="1">Group 4</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Subject (M/F)</td><td align="left" rowspan="1" colspan="1">20 (10/10)</td><td align="left" rowspan="1" colspan="1">12 (7/5)</td><td align="left" rowspan="1" colspan="1">7 (5/2)</td><td align="left" rowspan="1" colspan="1">10 (4/6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">30&#x000b7;9 &#x000b1;
2&#x000b7;6</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">33&#x000b7;83 &#x000b1;
1&#x000b7;2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">29&#x000b7;71 &#x000b1;
2&#x000b7;4</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">32&#x000b7;0 &#x000b1;
3&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoker (%)</td><td align="left" rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">33&#x000b7;3</td><td align="char" char="." rowspan="1" colspan="1">32&#x000b7;5</td><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV1%, predicted</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">81&#x000b7;1 &#x000b1;
2&#x000b7;2<xref rid="tf1-2" ref-type="table-fn">&#x02020;</xref><xref rid="tf1-3" ref-type="table-fn">&#x02021;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">97&#x000b7;2 &#x000b1;
4&#x000b7;8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">101&#x000b7;7 &#x000b1;
4&#x000b7;2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">107&#x000b7;8 &#x000b1;
6&#x000b7;3</td></tr><tr><td align="left" rowspan="1" colspan="1">Methacholine PC<sub>20</sub> (mg/ml)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2&#x000b7;1 &#x000b1; 1&#x000b7;4<xref rid="tf1-2" ref-type="table-fn">&#x02020;</xref><xref rid="tf1-3" ref-type="table-fn">&#x02021;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2&#x000b7;7 &#x000b1; 1&#x000b7;1<xref rid="tf1-4" ref-type="table-fn">&#x000a7;</xref><xref rid="tf1-5" ref-type="table-fn">&#x000b6;</xref></td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">25</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood eosinophil (%)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">5&#x000b7;1 &#x000b1; 0&#x000b7;7<xref rid="tf1-2" ref-type="table-fn">&#x02020;</xref><xref rid="tf1-3" ref-type="table-fn">&#x02021;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">6&#x000b7;2 &#x000b1; 1&#x000b7;5<xref rid="tf1-5" ref-type="table-fn">&#x000b6;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2&#x000b7;1 &#x000b1; 0&#x000b7;2</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">1&#x000b7;7 &#x000b1; 0&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin test to D.p. (%)</td><td align="left" rowspan="1" colspan="1">100<xref rid="tf1-1" ref-type="table-fn">*</xref><xref rid="tf1-3" ref-type="table-fn">&#x02021;</xref></td><td align="left" rowspan="1" colspan="1">0 <sup>&#x000a3;&#x000a3;</sup></td><td align="left" rowspan="1" colspan="1">100<xref rid="tf1-6" ref-type="table-fn">**</xref></td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Total IgE (U/ml)</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">571&#x000b7;5 &#x000b1;
127&#x000b7;6<xref rid="tf1-1" ref-type="table-fn">*</xref><xref rid="tf1-3" ref-type="table-fn">&#x02021;</xref><xref rid="tf1-5" ref-type="table-fn">&#x000b6;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">203&#x000b7;9 &#x000b1;
76&#x000b7;4<xref rid="tf1-5" ref-type="table-fn">&#x000b6;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">185&#x000b7;1 &#x000b1;
37&#x000b7;6<xref rid="tf1-6" ref-type="table-fn">**</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">22&#x000b7;8 &#x000b1;
6&#x000b7;2</td></tr><tr><td align="left" rowspan="1" colspan="1">Specific IgE, to D.p. antigen</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">3&#x000b7;7 &#x000b1; 0&#x000b7;2<xref rid="tf1-1" ref-type="table-fn">*</xref><xref rid="tf1-2" ref-type="table-fn">&#x02020;</xref><xref rid="tf1-3" ref-type="table-fn">&#x02021;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0 &#x000b1; 0<xref rid="tf1-4" ref-type="table-fn">&#x000a7;</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">2&#x000b7;7 &#x000b1; 0&#x000b7;3<xref rid="tf1-6" ref-type="table-fn">**</xref></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">0 &#x000b1; 0</td></tr></tbody></table><table-wrap-foot><fn><p>Specific IgE is presented as specific IgE class (grades 1&#x02013;6)
according to Unicap-specific IgE Unites (kU<sub>A</sub>/l).
Values are the means &#x000b1; s.e.m. <italic>P</italic>-values were
obtained using the Mann&#x02013;Whitney <italic>U</italic>-test or
the &#x003c7;<sup>2</sup> test. The following symbols represent
significant differences (<italic>P</italic> &#x0003c; 0&#x000b7;05)
between two groups:</p></fn><fn id="tf1-1"><label>*</label><p>between groups 1 and 2,</p></fn><fn id="tf1-2"><label>&#x02020;</label><p>between groups 1 and 3,</p></fn><fn id="tf1-3"><label>&#x02021;</label><p>between groups 1 and 4,</p></fn><fn id="tf1-4"><label>&#x000a7;</label><p>between groups 2 and 3,</p></fn><fn id="tf1-5"><label>&#x000b6;</label><p>between groups 2 and 4 and</p></fn><fn id="tf1-6"><label>**</label><p>between groups 3 and 4.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Production of cytokines and chemokines by PBCs in response to D.p.</title><p>Throughout this study, a bulk whole blood culture system was employed in which
peripheral blood was diluted at a 1 : 1 ratio with culture medium and used
without fractionation. To optimize IL-5 and eotaxin subfamilies production, PBCs
from group 1 (<italic>n</italic> = 7) were stimulated with various doses
of D.p. for different periods of time. Eotaxin-2 and IL-5 increased continuously
until 120 h after stimulation with a dose of 10 &#x000b5;g/ml D.p. and was
elevated significantly compared with those of unstimulated PBC, whereas
eotaxin-1 was decreased. No significant differences were found in eotaxin-3
production. Increased IL-5 and eotaxin-2 production by PBCs for 72-h stimulation
with D.p. antigen reached a plateau at a dose of 10 &#x000b5;g/ml D.p and
eotaxin-1 was significantly down-regulated upon exposure of PBCs in a
dose-dependent manner to D.p. antigen (<xref rid="fig01" ref-type="fig">Fig.
1a</xref>).</p><fig position="float" id="fig01"><label>Fig. 1</label><caption><p>(a) Time kinetics and dose&#x02013;responses of IL-5 and eotaxin family
chemokine production by D.p.-stimulated PBCs. PBCs were prepared from
group 1 (<italic>n</italic> = 7) and were stimulated with various
concentrations of D.p. for different lengths of time. Data are expressed
as the means &#x000b1; SEM. The statistical analysis was carried out
using the Wilcoxon signed rank test. *<italic>P</italic> &#x0003c;
0.05, **<italic>P</italic> &#x0003c; 0.01. (b) Production
of IL-5 and eotaxin subfamilies by D.p.-stimulated PBCs. PBCs were
stimulated with either medium or 10 &#x000b5;g D.p./ml for 72 h.
Groups 1, 2, 3, and 4 included 20, 12, 7, and 10 individual samples,
respectively. The amounts of cytokines were expressed as a fold increase
in which cytokine levels in the presence of D.p. were divided by those
in its absence. *<italic>P</italic> &#x0003c; 0.05,
**<italic>P</italic> &#x0003c; 0.01 vs. cytokine levels
in the absence of D.p. (c) Inhibition of D.p.-induced production of
eotaxin-2 and IL-5 by LPS. PBCs from group 1 (<italic>n</italic>
= 7) were treated with increasing concentrations of LPS in the
presence of D.p. (10 &#x000b5;g/ml) for 72 h, and the eotaxin-2
and IL-5 levels in the culture supernatants were determined.
*<italic>P</italic> &#x0003c; 0.05,
**<italic>P</italic> &#x0003c; 0.01 vs. D.p.-induced
production of eotaxin-2 and IL-5. Cytokine production was determined by
ELISA. (d) Percoll gradient-isolated leukocytes from group 1 were
stimulated with medium (panels 1, 2) or D.p. antigen (panels 3, 4),
cytospin, and either incubated with anti-human eotaxin-2 antibody
(panels 1, 3) or stained with Wright-Giemsa solution (panels 2, 4). Bar
=10 &#x000b5;m.</p></caption><graphic xlink:href="cei0147-0440-f1" position="float"/></fig><p>Next, we stimulated PBCs from subjects of four groups. To minimize the effect
derived from both different absolute and relative numbers of leucocytes in each
group and in each individual within the group, the results were expressed as a
fold increase of D.p. stimulation <italic>versus</italic> D.p. non-stimulation.
PBCs were obtained from four groups (group 1, <italic>n</italic> = 20;
group 2, <italic>n</italic> = 12; group 3, <italic>n</italic> = 7;
and group 4, <italic>n</italic> = 10) and were stimulated with D.p. (10
&#x000b5;g/ml) for 72 h. The significantly increased production of IL-5
was observed only in group 1, while eotaxin-2 was elevated in groups 1 and 3
(<xref rid="fig01" ref-type="fig">Fig. 1b</xref>). In contrast, eotaxin-1
production decreased significantly in groups 1 and 3. Eotaxin-3 was not changed
in the four groups (<xref rid="fig01" ref-type="fig">Fig. 1b</xref>). Eotaxin-2
production in groups 1 and 3 correlated strongly with the respective levels of
specific serum IgE to D.p. (<italic>r</italic> = 0&#x000b7;528,
<italic>P</italic> = 0&#x000b7;017 for group 1 and <italic>r</italic>
= 0&#x000b7;810, <italic>P</italic> = 0&#x000b7;027 for group 3)
(<xref rid="fig02" ref-type="fig">Fig. 2</xref>). Immunocytochemical and
Wright&#x02013;Giemsa staining of PBCs from group 1 showed that monocytes were
the eotaxin-2-producing cells (<xref rid="fig01" ref-type="fig">Fig.
1d</xref>).</p><fig position="float" id="fig02"><label>Fig. 2</label><caption><p>Correlation of eotaxin-2 production with plasma IgE specific to D.p. and
with production of eotaxin-2. Eotaxin-2 production in D.p.-stimulated
PBCs from asthmatics positive to D.p. (group 1, <italic>n</italic>
= 20; group 3, <italic>n</italic> = 7) was plotted against
the level of plasma IgE specific to it. The statistical analysis was
carried out using Spearman's rank test.</p></caption><graphic xlink:href="cei0147-0440-f2" position="float"/></fig></sec><sec><title>Inhibitory effect of LPS on D.p.-induced eotaxin-2 and IL-5
production</title><p>As eotaxin-2 and IL-5 levels increased following stimulation with D.p., the
production of these two cytokines in response to LPS was examined. PBCs from
group 1 (<italic>n</italic> = 7) were stimulated with increasing
concentrations of LPS in the presence of D.p. (10 &#x000b5;g/ml). The
results showed that eotaxin-2 and IL-5 production declined in a dose-dependent
fashion. Eotaxin-2 was inhibited completely (<italic>P</italic> =
0&#x000b7;01) and IL-5 was inhibited by 80% (<italic>P</italic> =
0&#x000b7;01) at 10 ng/ml LPS (<xref rid="fig01" ref-type="fig">Fig.
1c</xref>). To examine whether the inhibitory effect of LPS was mediated
through Toll-like receptor 4 (TLR4), a neutralization antibody to TLR4 was added
to PBC cultures from group 1 (<italic>n</italic> = 6) in the presence of
D.p. (10 &#x000b5;g/ml) and LPS (10 ng/ml). Eotaxin-2 and IL-5
production were partly restored by neutralization with anti-TLR4 in a
dose-dependent manner (<xref rid="fig03" ref-type="fig">Fig. 3a</xref>),
suggesting an inhibitory mechanism via TLR4. To identify which factor(s) mediate
the inhibitory effect of LPS on the D.p.-induced production of eotaxin-2 and
IL-5, production of cytokines (IL-5, IFN-&#x003b3;, IL-12 and IL-10) and eotaxins
was analysed in group 1 PBCs (<italic>n</italic> = 7) stimulated with LPS
alone. Among these, IFN-&#x003b3;, IL-12 and IL-10 were significantly
up-regulated upon the exposure of PBCs in a dose-dependent manner of LPS (<xref rid="fig03" ref-type="fig">Fig. 3b</xref>).</p><fig position="float" id="fig03"><label>Fig. 3</label><caption><p>(a) The effect of anti-TLR4 on LPS-induced inhibition of eotaxin-2 and
IL-5 production. PBCs were prepared from group 1 (<italic>n</italic>
= 6) and were incubated with different concentrations of
anti-TLR4 in the presence of LPS (10 ng/ml) and D.p. antigen (10
&#x000b5;g/ml) for 72 h. (b) IFN-&#x003b3;, IL-12, and IL-10
production by PBCs stimulated with LPS. Group 1 PBCs (<italic>n</italic>
= 7) were stimulated with LPS (0.1&#x02013;100 ng/ml) for
72 h. The amounts of cytokine were measured by ELISA. Data are expressed
as the means &#x000b1; SEM. The statistical analysis was carried out
using the Wilcoxon signed rank test. *<italic>P</italic> &#x0003c;
0.05, **<italic>P</italic> &#x0003c; 0.01.</p></caption><graphic xlink:href="cei0147-0440-f3" position="float"/></fig></sec><sec><title>LPS inhibits D.p.-induced production of IL-5 and eotaxin-2 via IL-10
production</title><p>The three cytokines induced by LPS were examined individually for their
inhibitory effect on the production of eotaxin-2 and IL-5 by D.p.-stimulated
PBCs from group 1 (<italic>n</italic> = 8). IL-10 inhibited eotaxin-2 and
IL-5 production almost completely (<xref rid="fig04" ref-type="fig">Fig.
4a</xref>). In contrast, IFN-&#x003b3; significantly augmented the production
of both cytokines, and IL-12 had no effect. Anti-IL-10R&#x003b1; suppressed
dose-dependently the inhibitory effect of LPS on D.p.-stimulated IL-5 production
but not eotaxin-2 production (<xref rid="fig04" ref-type="fig">Fig. 4b</xref>),
suggesting that a signal transmitted through the IL-10R effectively blocks IL-5
production by D.p.-primed Th2 cells, yet is not effective for monocyte eotaxin-2
production. RT&#x02013;PCR analysis showed that the LPS-mediated inhibition as
well as the restoration of IL-5 mRNA expression by anti-IL-10R&#x003b1; indeed
occurred at the transcriptional level (<xref rid="fig04" ref-type="fig">Fig.
4c</xref>). The neutralization of eotaxin-2 mRNA expression by
anti-IL-10R&#x003b1; was not observed, indicating that the inhibitory effects of
LPS on D.p.-induced IL-5 and eotaxin-2 production are regulated differently.</p><fig position="float" id="fig04"><label>Fig. 4</label><caption><p>The inhibitory effects of IL-10 on D.p. antigen-stimulated production of
eotaxin-2 and IL-5. PBCs were prepared from group 1 (<italic>n</italic>
= 8). (a) PBCs were stimulated with D.p. (10 &#x000b5;g/ml)
for 72 h in the absence or presence of recombinant IL-10, IFN-&#x003b3;,
or IL-12 (each 0.01&#x02013;1 ng/ml). (b) PBCs were stimulated
with D.p. (10 &#x000b5;g/ml) and LPS (10 ng/ml) in the
presence of increasing concentrations of anti-IL-10R&#x003b1;
(0.01&#x02013;1 &#x000b5;g/ml) for 72 h, and eotaxin-2 and IL-5
production was evaluated. The statistical analysis was carried out using
the Wilcoxon signed rank test. *<italic>P</italic> &#x0003c; 0.05,
**<italic>P</italic> &#x0003c; 0.01. (c) PBMCs from
group 1 (<italic>n</italic> = 8) and were stimulated under the
indicated conditions for 72 h.</p></caption><graphic xlink:href="cei0147-0440-f4" position="float"/></fig></sec></sec><sec><title>Discussion</title><p>We employed an <italic>ex vivo</italic> stimulation of peripheral blood cells (PBCs)
that were obtained from four groups of asthmatics and non-asthmatics with or without
specific IgE to mite D.p. PBC contains lymphocytes, monocytes and other leucocytes.
It also contains an array of protein and non-protein factors that may influence the
availability of the antigen and LPS used. Thus it functionally represents the
<italic>in vivo</italic> milieu more accurately than do purified peripheral
blood leucocytes or combinations thereof.</p><p>Stimulation of PBCs with D.p. resulted in characteristic expression patterns of IL-5
and eotaxin subfamily chemokines. We identified increased IL-5 and eotaxin-2
production in D.p.-stimulated PBCs from the specific IgE-positive (group 1) and
monocytes as a major producer of eotaxin-2. This result indicates the strict
dependence of IL-5 and eotaxin-2 production on sensitization with specific antigens.
IL-5 synthesis was observed only in PBCs from group 1. This result is in agreement
with a previous study in which allergen-induced IL-5 production by PBMC from
sensitized atopic subjects with symptoms, but not subjects without symptoms, is
elevated [<xref rid="b14" ref-type="bibr">14</xref>].</p><p>CD23, a low-affinity receptor of IgE (Fc&#x000e5;RII), is expressed at a much higher
level in monocytes from allergic asthmatics than in cells from normal individuals
[<xref rid="b28" ref-type="bibr">28</xref>]. It is therefore
speculated that D.p. may form a complex with circulating specific IgE to induce
eotaxin-2 production through the engagement of abundant CD23 on monocytes from
allergic subjects. As a result, eotaxin-2 production may be related to the presence
of specific IgE. Our data demonstrate that eotaxin-1 is down-regulated and eotaxin-2
is up-regulated by D.p., while eotaxin-3 remains unchanged. This may be due to
different cell sources of each eotaxin. While monocytes are a major source of
eotaxin-2, eotaxin-1 and 3 are produced mainly by epithelial cells [<xref rid="b9" ref-type="bibr">9</xref>]. Limited studies have demonstrated the
differential expression and roles of eotaxin subfamilies in regulating the kinetics
of eosinophil recruitment during allergic inflammation [<xref rid="b11" ref-type="bibr">11</xref>,<xref rid="b29" ref-type="bibr">29</xref>]. However,
experimental asthma models using eotaxin 1 and/or eotaxin 2 knock-out mice
showed a dominant role of eotaxin-2 in ovalbumin (OVA)-induced airway eosinophilia
[<xref rid="b13" ref-type="bibr">13</xref>], in spite of a
co-operative role for eotaxin-1 and eotaxin-2 in recruitment of eosinophils to the
lung tissue. We have shown that polymorphism in the gene encoding eotaxin-2, but not
eotaxin-1, is associated with a risk of asthma [<xref rid="b30" ref-type="bibr">30</xref>] and correlates with plasma eotaxin-2 levels
[<xref rid="b31" ref-type="bibr">31</xref>]. These data, including
ours, may suggest a dominant role of eotaxin-2 among the eotaxin subfamily in
peripheral circulation of atopic asthma.</p><p>The effect of endotoxin exposure in asthma is still controversial. The beneficial
effects of LPS are thought to be mediated by enhanced secretion of IFN-&#x003b3; and
IL-12 [<xref rid="b32" ref-type="bibr">32</xref>,<xref rid="b33" ref-type="bibr">33</xref>], whereas LPS affects asthmatics adversely by
enhancing established airway inflammation and airway obstruction [<xref rid="b16" ref-type="bibr">16</xref>]. In the present study, we showed
that LPS inhibited dose-dependently the production of IL-5 and eotaxin-2 in response
to specific antigen; thus only IL-10 almost completely inhibited antigen-induced
production of IL-5 and eotaxin-2 (<xref rid="fig01" ref-type="fig">Figs
1</xref>&#x02013;<xref rid="fig03" ref-type="fig">3</xref>). The other novel
finding of our study is that blocking the functioning receptor of IL-10
(IL-10R&#x003b1;) restored the inhibitory effect of LPS only on IL-5 production
(<xref rid="fig04" ref-type="fig">Fig. 4</xref>). These data suggest that the
effect of LPS against the manifestation of allergic asthma is achieved by reducing
eosinophilic inflammation through the up-regulation of IL-10 production. In support
of this finding, IL-10 has been shown to exhibit anti-allergic activity in
sensitized mice by preventing IL-5 release and antigen-induced
CD4<sup>+</sup> T lymphocyte and eosinophil accumulation [<xref rid="b22" ref-type="bibr">22</xref>].</p><p>Systemic administration of endotoxin to healthy subjects produced a selective
induction of Th1, as confirmed by increased IL-2 production <italic>versus</italic>
decreased IFN-gamma production and Th2 chemokine ligands such as CCR4 receptor
[<xref rid="b34" ref-type="bibr">34</xref>]. These <italic>in
vivo</italic> data were not in agreement with ours in terms of different
patterns of IFN-gamma production. It would be interesting to evaluate whether IL-10
production is elevated in a human endotoxin model, but this has not yet been
attempted. In contrast to systemic administration, inhalation of endotoxin induced
different patterns of reaction in the airways. Inhalation of endotoxin has been
recognized as an important factor in the aetiology of occupational lung diseases,
including non-allergic asthma [<xref rid="b35" ref-type="bibr">35</xref>]. Eosinophilic inflammation is generally considered to be the main
feature of allergic asthmatic airways and is presumed to be crucial in the
pathogenesis of allergic asthma [<xref rid="b36" ref-type="bibr">36</xref>]. Endotoxin in house dust is associated with exacerbations of
pre-existing asthma in children and adults [<xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b37" ref-type="bibr">37</xref>], and induces
neutrophilic airways inflammation via IL-8 secretion [<xref rid="b38" ref-type="bibr">38</xref>]. The switching of eosinophilic inflammation into
neutrophilic inflammation in the acute exacerbation of allergic asthma is
contributed mainly by up-regulation of neutrophilic chemokines such as IL-8. In
addition, down-regulation of IL-5 and eotaxin may be one mechanism to reduce the
eosinophilic inflammation in the LPS-induced neutrophilic airway inflammation of
asthmatics, as shown in experimental models [<xref rid="b39" ref-type="bibr">39</xref>], although this has not been revealed in the airways of
asthmatics. IL-10 may exert an inhibitory effect on eotaxin-2 production via another
pathway such as IL-10R&#x003b2;[<xref rid="b40" ref-type="bibr">40</xref>], or an unknown pathway. Intriguingly, IFN-&#x003b3; treatment
enhanced the production of IL-5 and eotaxin-2 by antigen-stimulated PBCs, while
IL-12 had no effect (<xref rid="fig04" ref-type="fig">Fig. 4a</xref>). This
observation is in line with previous findings that the suppression of airway
eosinophilia and AHR by LPS [<xref rid="b41" ref-type="bibr">41</xref>] or killed mycobacteria [<xref rid="b42" ref-type="bibr">42</xref>] is not attributable to a Th1 shift.</p><p>In summary, two important conclusions can be drawn from our results: first, specific
antigen-stimulated whole-blood cultures from asthmatics and normal controls with or
without specific IgE to D.p. produce unique patterns of IL-5 and eotaxin-2.
Secondly, LPS inhibits antigen-induced production of IL-5 and eotaxin-2 via IL-10
secretion. The inhibitory effect of endotoxin may be associated with its ability to
attenuate eosinophilic inflammation or eosinophil-mediated immune responses.</p></sec></body><back><ack><p>This work was supported by a grant from Korea Research Foundation
(KRF-2003&#x02013;041-E00123).</p></ack><ref-list><title>References</title><ref id="b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cambell</surname><given-names>P</given-names></name><name><surname>Weiss</surname><given-names>U</given-names></name></person-group><article-title>Allergy and asthma</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>B1</fpage><lpage>38</lpage></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>KF</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Cytokines in asthma</article-title><source>Thorax</source><year>1999</year><volume>54</volume><fpage>825</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10456976</pub-id></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>ME</given-names></name><name><surname>Hogan</surname><given-names>SP</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Rothenberg</surname><given-names>ME</given-names></name></person-group><article-title>Overview</article-title><source>Chemokines in allergic disease</source><year>2000</year><publisher-loc>New York</publisher-loc><publisher-name>Marcel Dekker, Inc.</publisher-name><fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Zepeda</surname><given-names>EA</given-names></name><name><surname>Rothenberg</surname><given-names>ME</given-names></name><name><surname>Weremowicz</surname><given-names>S</given-names></name><name><surname>Sarafi</surname><given-names>MN</given-names></name><name><surname>Morton</surname><given-names>CC</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name></person-group><article-title>Genomic organization, complete sequence, and chromosomal location
of the gene for human eotaxin (SCYA11), an eosinophil-specific CC
chemokine</article-title><source>Genomics</source><year>1997</year><volume>41</volume><fpage>471</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9169149</pub-id></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomiyama</surname><given-names>H</given-names></name><name><surname>Osborne</surname><given-names>LR</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name><etal/></person-group><article-title>Assignment of the human CC chemokine MPIF-2/eotaxin-2
(SCYA24) to chromosome 7q11.23</article-title><source>Genomics</source><year>1998</year><volume>49</volume><fpage>339</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">9598329</pub-id></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>RF</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name><name><surname>Hu</surname><given-names>SM</given-names></name><name><surname>McDuffie</surname><given-names>JE</given-names></name><name><surname>Huber-Lang</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>MM</given-names></name></person-group><article-title>Molecular cloning and characterization of a novel human CC
chemokine, SCYA26</article-title><source>Genomics</source><year>1999</year><volume>58</volume><fpage>313</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10373330</pub-id></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>JR</given-names></name><name><surname>Imburgia</surname><given-names>C</given-names></name><name><surname>Dul</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cloning and functional characterization of a novel human CC
chemokine that binds to the CCR3 receptor and activates human
eosinophils</article-title><source>J Leukoc Biol</source><year>1997</year><volume>62</volume><fpage>667</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">9365122</pub-id></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>VP</given-names></name><name><surname>Kreider</surname><given-names>BL</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Molecular and functional characterization of two novel human C-C
chemokines as inhibitors of two distinct classes of myeloid
progenitors</article-title><source>J Exp Med</source><year>1997</year><volume>185</volume><fpage>1163</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">9104803</pub-id></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komiya</surname><given-names>A</given-names></name><name><surname>Nagase</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><etal/></person-group><article-title>Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in
human bronchial epithelial cells</article-title><source>Cell Immunol</source><year>2003</year><volume>225</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">14698143</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Hogan</surname><given-names>SP</given-names></name><name><surname>Mahalingam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13
production and airway eosinophilia and hyperreactivity</article-title><source>J Allergy Clin Immunol</source><year>2003</year><volume>112</volume><fpage>935</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">14610483</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berkman</surname><given-names>N</given-names></name><name><surname>Ohnona</surname><given-names>S</given-names></name></person-group><article-title>Eotaxin-3 but not eotaxin gene expression is upregulated in
asthmatics 24 hours after allergen challenge</article-title><source>Am J Respir Cell Mol Biol</source><year>2001</year><volume>24</volume><fpage>682</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11415932</pub-id></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravensberg</surname><given-names>AJ</given-names></name><name><surname>Ricciardolo</surname><given-names>FL</given-names></name><name><surname>zan Schadewijk</surname><given-names>A</given-names></name><etal/></person-group><article-title>Eotaxin-2 and eotaxin-3 expression is associated with persistent
eosinophilic bronchial inflammation in patients with asthma after allergen
challenge</article-title><source>J Allergy Clin Immunol</source><year>2005</year><volume>115</volume><fpage>779</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">15805998</pub-id></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname><given-names>SM</given-names></name><name><surname>Zimmermann</surname><given-names>N</given-names></name><name><surname>Stringer</surname><given-names>KF</given-names></name><name><surname>Karow</surname><given-names>ML</given-names></name><name><surname>Rothenberg</surname><given-names>ME</given-names></name></person-group><article-title>The eotaxin chemokines and CCR3 are fundamental regulators of
allergen-induced pulmonary eosinophilia</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>5341</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">16210640</pub-id></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Till</surname><given-names>S</given-names></name><name><surname>Dickason</surname><given-names>R</given-names></name><name><surname>Huston</surname><given-names>D</given-names></name><etal/></person-group><article-title>IL-5 secretion by allergen-stimulated CD4+ T cells in
primary culture: relationship to expression of allergic
disease</article-title><source>J Allergy Clin Immunol</source><year>1997</year><volume>99</volume><fpage>563</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9111503</pub-id></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>O</given-names></name><name><surname>Ginanni</surname><given-names>R</given-names></name><name><surname>Le Bon</surname><given-names>B</given-names></name><name><surname>Content</surname><given-names>J</given-names></name><name><surname>Duchateau</surname><given-names>J</given-names></name><name><surname>Sergysels</surname><given-names>R</given-names></name></person-group><article-title>Inflammatory response to acute inhalation of endotoxin in
asthmatic patients</article-title><source>Am Rev Respir Dis</source><year>1992</year><volume>146</volume><fpage>352</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1489124</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>O</given-names></name><name><surname>Kips</surname><given-names>J</given-names></name><name><surname>Duchateau</surname><given-names>J</given-names></name><etal/></person-group><article-title>Severity of asthma is related to endotoxin in house
dust</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>154</volume><fpage>1641</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8970348</pub-id></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldridge</surname><given-names>MW</given-names></name><name><surname>Peden</surname><given-names>DB</given-names></name></person-group><article-title>Allergen provocation augments endotoxin-induced nasal
inflammation in subjects with atopic asthma</article-title><source>J Allergy Clin Immunol</source><year>2000</year><volume>105</volume><fpage>475</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10719296</pub-id></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gereda</surname><given-names>JE</given-names></name><name><surname>Leung</surname><given-names>DY</given-names></name><name><surname>Thatayatikom</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relation between house-dust endotoxin exposure, type 1 T-cell
development, and allergen sensitization in infants at high risk of
asthma</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1680</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10905243</pub-id></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>PG</given-names></name><name><surname>Sly</surname><given-names>PD</given-names></name></person-group><article-title>Prevention of adult asthma by early intervention during
childhood: potential value of new generation immunomodulatory
drugs</article-title><source>Thorax</source><year>2000</year><volume>55</volume><fpage>700</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10899250</pub-id></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulic</surname><given-names>MK</given-names></name><name><surname>Wale</surname><given-names>JL</given-names></name><name><surname>Holt</surname><given-names>PG</given-names></name><name><surname>Sly</surname><given-names>PD</given-names></name></person-group><article-title>Modification of the inflammatory response to allergen challenge
after exposure to bacterial lipopolysaccharide</article-title><source>Am J Respir Cell Mol Biol</source><year>2000</year><volume>22</volume><fpage>604</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">10783133</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>SC</given-names></name><name><surname>Madden</surname><given-names>KB</given-names></name><name><surname>Adamovicz</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Effects of IL-12 on <italic>in vivo</italic> cytokine gene
expression and Ig isotype selection</article-title><source>J Immunol</source><year>1994</year><volume>152</volume><fpage>1047</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">7905496</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuany-Amorim</surname><given-names>C</given-names></name><name><surname>Creminon</surname><given-names>C</given-names></name><name><surname>Nevers</surname><given-names>MC</given-names></name><name><surname>Nahori</surname><given-names>MA</given-names></name><name><surname>Vargaftig</surname><given-names>BB</given-names></name><name><surname>Pretolani</surname><given-names>M</given-names></name></person-group><article-title>Modulation by IL-10 of antigen-induced IL-5 generation, and
CD4+ T lymphocyte and eosinophil infiltration into the mouse
peritoneal cavity</article-title><source>J Immunol</source><year>1996</year><volume>157</volume><fpage>377</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8683140</pub-id></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><collab>Global Initiative for Asthma (GINA)</collab><article-title>Global strategy for asthma management and
prevention</article-title><source>J Allergy Clin Immunol</source><year>2002</year><volume>110</volume><fpage>S141</fpage><lpage>219</lpage><comment>NHLBI/WHO workshop report, Bethesda, MD National Institutes of
Health National Heart, Lung, and Blood Institute; 2002. NIH publication no.
02&#x02013;3659.</comment><pub-id pub-id-type="pmid">12542074</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><collab>American Thoracic Society</collab><article-title>Standards for the diagnosis and care of patients with chronic
obstructive pulmonary disease (COPD) and asthma</article-title><source>Am Rev Respir Dis</source><year>1987</year><volume>136</volume><fpage>225</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">3605835</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahm</surname><given-names>DH</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Hong</surname><given-names>CS</given-names></name></person-group><article-title>Effects of autologous sera on immediate and late skin reaction to
the house dust mite in atopic individuals</article-title><source>Yonsei Med J</source><year>1995</year><volume>36</volume><fpage>137</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">7618361</pub-id></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleich</surname><given-names>GJ</given-names></name><name><surname>Jones</surname><given-names>RT</given-names></name></person-group><article-title>Measurement of IgE antibodies by the radioallergosorbent test. I.
Technical considerations in the performance of the test</article-title><source>J Allergy Clin Immunol</source><year>1975</year><volume>55</volume><fpage>334</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">1168214</pub-id></element-citation></ref><ref id="b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Menz</surname><given-names>G</given-names></name><name><surname>Ying</surname><given-names>S</given-names></name><etal/></person-group><article-title>The immunopathology of extrinsic (atopic) and intrinsic
(non-atopic) asthma: more similarities than differences</article-title><source>Immunol Today</source><year>1999</year><volume>20</volume><fpage>528</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10529782</pub-id></element-citation></ref><ref id="b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Mascali</surname><given-names>JJ</given-names></name><name><surname>Smith</surname><given-names>H</given-names></name><name><surname>Rosenwasser</surname><given-names>LJ</given-names></name><name><surname>Borish</surname><given-names>L</given-names></name></person-group><article-title>Regulation of low affinity IgE receptor (CD23) expression on
mononuclear phagocytes in normal and asthmatic subjects</article-title><source>J Immunol</source><year>1992</year><volume>149</volume><fpage>2823</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1401914</pub-id></element-citation></ref><ref id="b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Zeibecoglou</surname><given-names>K</given-names></name><etal/></person-group><article-title>Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES,
monocyte chemoattractant protein-3 (MCP-3), and MCP-4, and C-C chemokine
receptor 3 expression in bronchial biopsies from atopic and nonatopic
(intrinsic) asthmatics</article-title><source>J Immunol</source><year>1999</year><volume>163</volume><fpage>6321</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10570327</pub-id></element-citation></ref><ref id="b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>HD</given-names></name><name><surname>Kim</surname><given-names>LH</given-names></name><name><surname>Park</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Association of eotaxin gene family with asthma and serum total
IgE</article-title><source>Hum Mol Genet</source><year>2003</year><volume>312</volume><fpage>1279</fpage><lpage>85</lpage></element-citation></ref><ref id="b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Association of eotaxin-2 gene polymorphisms with plasma eotaxin-2
concentration</article-title><source>J Hum Genet</source><year>2005</year><volume>50</volume><fpage>118</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15744457</pub-id></element-citation></ref><ref id="b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwamoto</surname><given-names>I</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name></person-group><article-title>Interferon gamma regulates antigen-induced eosinophil recruitment
into the mouse airways by inhibiting the infiltration of CD4+ T
cells</article-title><source>J Exp Med</source><year>1993</year><volume>177</volume><fpage>573</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8093895</pub-id></element-citation></ref><ref id="b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kips</surname><given-names>JC</given-names></name><name><surname>Brusselle</surname><given-names>GJ</given-names></name><name><surname>Joos</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Interleukin-12 inhibits antigen-induced airway
hyperresponsiveness in mice</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>153</volume><fpage>535</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8564093</pub-id></element-citation></ref><ref id="b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De</surname><given-names>AK</given-names></name><name><surname>Miller-Graziano</surname><given-names>CL</given-names></name><name><surname>Calvano</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Selective activation of peripheral blood T cell subsets by
endotoxin infusion in healthy human subjects corresponds to differential
chemokine activation</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>6155</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16237112</pub-id></element-citation></ref><ref id="b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenker</surname><given-names>MB</given-names></name><name><surname>Christiani</surname><given-names>D</given-names></name><name><surname>Cormier</surname><given-names>Y</given-names></name></person-group><article-title>Respiratory health hazards in agriculture</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>158</volume><fpage>S1</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">9817727</pub-id></element-citation></ref><ref id="b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>PG</given-names></name><name><surname>Macaubas</surname><given-names>C</given-names></name><name><surname>Stumbles</surname><given-names>PA</given-names></name><name><surname>Sly</surname><given-names>PD</given-names></name></person-group><article-title>The role of allergy in the development of asthma</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>B12</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10586890</pub-id></element-citation></ref><ref id="b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>MC</given-names></name><name><surname>Naspitz</surname><given-names>CK</given-names></name><name><surname>Fernandez-Cladas</surname><given-names>E</given-names></name><name><surname>Lockey</surname><given-names>RF</given-names></name><name><surname>Mimica</surname><given-names>I</given-names></name><name><surname>Sole</surname><given-names>D</given-names></name></person-group><article-title>Endotoxin exposure and symptoms in asthmatic
children</article-title><source>Pediatr Allergy Immunol</source><year>1997</year><volume>8</volume><fpage>121</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9532251</pub-id></element-citation></ref><ref id="b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nightingale</surname><given-names>JA</given-names></name><name><surname>Rogers</surname><given-names>DF</given-names></name><name><surname>Hart</surname><given-names>LA</given-names></name><name><surname>Kharitonov</surname><given-names>SA</given-names></name><name><surname>Chung</surname><given-names>KF</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Effect of inhaled endotoxin on induced sputum in normal, atopic,
and atopic asthmatic subjects</article-title><source>Thorax</source><year>1998</year><volume>53</volume><fpage>563</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">9797755</pub-id></element-citation></ref><ref id="b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>SS</given-names></name><name><surname>Lukacs</surname><given-names>NW</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name></person-group><article-title>Eotaxin/CCL11 is a negative regulator of neutrophil
recruitment in a murine model of endotoxemia</article-title><source>Exp Mol Pathol</source><year>2002</year><volume>73</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12127048</pub-id></element-citation></ref><ref id="b40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>SD</given-names></name><name><surname>Di Marco</surname><given-names>F</given-names></name><name><surname>Hooley</surname><given-names>J</given-names></name><etal/></person-group><article-title>The orphan receptor CRF2-4 is an essential subunit of the
interleukin 10 receptor</article-title><source>J Exp Med</source><year>1998</year><volume>187</volume><fpage>571</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9463407</pub-id></element-citation></ref><ref id="b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>D</given-names></name><name><surname>Keller</surname><given-names>AC</given-names></name><name><surname>Faquim-Mauro</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Bacterial lipopolysaccharide signaling through Toll-like receptor
4 suppresses asthma-like responses via nitric oxide synthase 2
activity</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>1001</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12847273</pub-id></element-citation></ref><ref id="b42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuany-Amorim</surname><given-names>C</given-names></name><name><surname>Sawicka</surname><given-names>E</given-names></name><name><surname>Manlius</surname><given-names>C</given-names></name><etal/></person-group><article-title>Suppression of airway eosinophilia by killed
<italic>Mycobacterium vaccae</italic>-induced allergen-specific
regulatory T-cells</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><fpage>625</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12042815</pub-id></element-citation></ref></ref-list></back></article>
